The DOI matches its Crossref record; 38 of the 39 references it cites were found in a registry or an index; 37 of the 43 sources its claims cite were checked for support.
Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia
Open accessAbstract
We describe in vivo follow-up PET imaging and postmortem findings from an autosomal dominant Alzheimer's disease (ADAD) PSEN1 E280A carrier who was also homozygous for the APOE3 Christchurch (APOE3ch) variant and was protected against Alzheimer's symptoms for almost three decades beyond the expected age of onset. We identified a distinct anatomical pattern of tau pathology with atypical accumulation in vivo and unusual postmortem regional distribution characterized by sparing in the frontal cortex and severe pathology in the occipital cortex. The frontal cortex and the hippocampus, less affected than the occipital cortex by tau pathology, contained Related Orphan Receptor B (RORB) positive neurons, homeostatic astrocytes and higher APOE expression. The occipital cortex, the only cortical region showing cerebral amyloid angiopathy (CAA), exhibited a distinctive chronic inflammatory microglial profile and lower APOE expression. Thus, the Christchurch variant may impact the distribution of tau pathology, modulate age at onset, severity, progression, and clinical presentation of ADAD, suggesting possible therapeutic strategies.
Overview
CoChat Summary
TL;DR
In a PSEN1 E280A carrier homozygous for the APOE3 Christchurch variant, longitudinal PET and postmortem analyses showed protection from Alzheimer’s dementia for almost three decades but a distinct tau pattern with occipital-predominant pathology and frontal sparing. Regional snRNA-seq linked less affected frontal and hippocampal areas to RORB-positive neurons, homeostatic astrocytes and higher APOE expression, while occipital cortex showed CAA, inflammatory microglia and lower APOE expression.
Key findings
- The patient remained protected from Alzheimer’s symptoms for almost three decades beyond the expected age of onset; she was diagnosed with mild cognitive impairment at 72, mild dementia at 75, and died at 77 from metastatic melanoma.
- Tau PET showed relative sparing of temporal and parietal neocortex with abnormally elevated occipital tau; annualized tau increases were entorhinal cortex 6.9%/year, amygdala 5.1%/year, and lateral occipital cortex 11.5%/year.
- Postmortem brain weighed 894.3 g and was classified Braak VI, Thal V, CERAD C, A3B3C3; tau was highest in hippocampus, amygdala and occipital cortex (Brodmann areas 17 and 18) with negligible frontal tau, while Aβ showed a fronto-temporal predominant pattern and the occipital cortex was the only neocortical structure with CAA.
- snRNA-seq identified RORB-positive neurons in frontal cortex and hippocampus; APOE expression showed a gradient from high in frontal cortex to low in occipital cortex, with astrocytic homeostatic genes correlating with APOE in frontal cortex/hippocampus and microglial immune-response genes correlating in occipital cortex.
Methods
- Case report with longitudinal clinical assessments, structural MRI, 11C-Pittsburgh Compound B and 18F-Flortaucipir PET at ages 73 and 75, compared with typical PSEN1 E280A carriers and older sporadic AD patients.
- Postmortem neuropathology at age 77 examined 17 brain regions with H&E and immunohistochemistry for Aβ, hyperphosphorylated tau, Iba1, TMEM119, CD68, GFAP, RORB and ApoE, plus electron microscopy and ImageJ quantification with Spearman correlation analyses.
- Single-nuclei RNA sequencing was performed on frontal cortex, hippocampus and occipital cortex using 10x Chromium; data were processed in Seurat with clustering, differential expression, APOE correlation and gene ontology analyses, and microglial signatures were compared with published acute and chronic neurodegenerative profiles.
Limitations
- The paper states the most prominent limitation is that findings are based on analyses of one case, and that mere associations cannot address causal connections by themselves.
- The paper notes that locating another ADAD case homozygous for the APOE3ch variant might be very challenging, and that further studies involving more protected patients would be ideal to compare and validate the findings.
- The paper also states that gene expression does not necessarily represent actual protein levels and that further studies would be necessary to confirm the pathways involved.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
28 Valid · 0 Not valid · 3 Not checked · 104 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In contrast, Aβ pathology distribution showed an expected [6, 32] fronto-temporal predominant pattern (Fig. 2A–C, Supp. Figure 2, online resource).”
§ Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia > Results > Neuropathological findings
What the sources say
- Partly supportedcites [6] Desikan RS, Cabral HJ, Hess CP, Dillon WP, Glastonbury CM, Weiner MW et al (2009) Automated MRI measures identify individuals with mild cognitive impairment and Alzheimer’s disease. Brain 132:2048–2057. https://doi.org/10.1093/brain/awp123 sourceExperimental — accuracy not yet measured
The Discussion (page unavailable) describes Aβ-associated amyloid changes in the entorhinal cortex and neocortical regions, which supports a temporal component. It does not describe frontal involvement as predominant or establish a fronto-temporal distribution; the study's Results report MRI measures rather than a map of Aβ pathology. (LLM, conf=0.83)
- Partly supportedcites [32] Sepulveda-Falla D, Chavez-Gutierrez L, Portelius E, Vélez JI, Dujardin S, Barrera-Ocampo A et al (2021) A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer’s disease. Acta Neuropathol 141:217–233. https://doi.org/10.1007/s00401-020-02249-0 sourceExperimental — accuracy not yet measured
The Results section, Fig. 2 caption (page unavailable), reports Aβ staining and plaque-load measurements in the frontal, temporal, parietal, and occipital cortices. Our copy does not state that pathology was predominantly fronto-temporal or compare those regions in a way that establishes that pattern. (LLM, conf=0.78)
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, the integration of these pathological assessments following the NIAA guidelines gives a classification of AD neuropathological changes of A3B3C3 [16], that can be interpreted as high, similar to other PSEN1E280A cases.”
§ Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia > Results > Neuropathological findings
What the sources say
- Supportedcites [16] Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC et al (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 8:1–13. https://doi.org/10.1016/j.jalz.2011.10.007 source
The Classification section defines the A, B and C scores, including A3, B3 and C3. The Reporting section explicitly gives “A3, B3, C3” as a classification of Alzheimer disease neuropathologic changes. The particular case score comes from the citing authors’ assessments; the cited guidelines support the classification method. (LLM, conf=0.91)
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Nevertheless, some cases belonging to a large kindred carrying the presenilin-1 (PSEN1) E280A mutation have shown delayed onset, suggesting possible mechanisms of disease modulation [31, 32].”
§ Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia > Introduction
What the sources say
- Partly supportedcites [31] Sanchez JS, Hanseeuw BJ, Lopera F, Sperling RA, Baena A, Bocanegra Y et al (2021) Longitudinal amyloid and tau accumulation in autosomal dominant Alzheimer’s disease: findings from the Colombia-Boston (COLBOS) biomarker study. Alzheimers Res Ther 13:27. https://doi.org/10.1186/s13195-020-00765-5 sourceExperimental — accuracy not yet measured
The Background describes the large Colombian PSEN1 E280A kindred, and the Discussion reports one carrier who retained cognitive function into her seventies despite substantial amyloid burden. The Discussion also suggests that factors beyond amyloid may affect disease progression. Our copy supports an unusually delayed case, but does not establish the claim’s plural “some cases.” Pages are not available in our copy. (LLM, conf=0.85)
- Supportedcites [32] Sepulveda-Falla D, Chavez-Gutierrez L, Portelius E, Vélez JI, Dujardin S, Barrera-Ocampo A et al (2021) A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer’s disease. Acta Neuropathol 141:217–233. https://doi.org/10.1007/s00401-020-02249-0 source
The Introduction describes the Colombian PSEN1 E280A kindred as exceptionally large and reports ages of onset ranging from 39 to 70 years. The Discussion identifies factors that may modify pathology and delay onset, supporting the suggestion of disease-modulating mechanisms. (LLM, conf=0.93)
hedgedstates a possible cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“We describe in vivo follow-up PET imaging and postmortem findings from an autosomal dominant Alzheimer’s disease (ADAD) PSEN1 E280A carrier who was also homozygous for the APOE3 Christchurch (APOE3ch) variant and was protected against Alzheimer’s symptoms for almost three decades beyond the expected age of onset.”
- Also stated in: § Introduction · plain
“We previously reported a PSEN1 E280A mutation carrier from the world’s largest known autosomal dominant Alzheimer’s disease (ADAD) kindred who was spared from Alzheimer’s symptoms until her seventies, nearly three decades after the typical age of clinical onset among mutation carriers in this kindred [1].”
§ Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia > Abstract
What the sources say
- Supportedcites [1] Arboleda-Velasquez JF, Lopera F, O’Hare M, Delgado-Tirado S, Marino C, Chmielewska N et al (2019) Resistance to autosomal dominant Alzheimer’s disease in an APOE3 Christchurch homozygote: a case report. Nat Med 25:1680–1683. https://doi.org/10.1038/s41591-019-0611-3 source
The paper’s opening section reports that the PSEN1 E280A carrier did not develop mild cognitive impairment until her seventies, nearly three decades after the kindred’s typical onset age of 44. It also confirms that she had two copies of the APOE3 Christchurch variant. (LLM, conf=0.94)
plainstates a causeSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Also stated in: § Introduction · plain
Every source the paper cites for this claim was checked and supports it.
In the paper
“Furthermore, the integration of these pathological assessments following the NIAA guidelines gives a classification of AD neuropathological changes of A3B3C3 [16], that can be interpreted as high, similar to other PSEN1E280A cases.”
§ Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia > Results > Neuropathological findings
What the sources say
- Supportedcites [16] Hyman BT, Phelps CH, Beach TG, Bigio EH, Cairns NJ, Carrillo MC et al (2012) National Institute on Aging-Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease. Alzheimers Dement 8:1–13. https://doi.org/10.1016/j.jalz.2011.10.007 source
The Classification section defines the A, B and C scores, and the Reporting section gives A3, B3, C3 as an example of an AD neuropathologic classification. The guidelines support interpreting that score as a high level of neuropathologic change. The comparison with other PSEN1E280A cases follows the citation and is the citing authors’ own comparison. (LLM, conf=0.90)
plainstates an associationSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
63 more claims · 4 with their cited sources checked
Create a free account to see all 135 claims and every source verdict.
- Probably not a substantial claim. 30
- It may state two separate claims as one. 47
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Post mortem studies revealed that the brain of a homozygous APOE3Ch carrier exhibited minimal astrocytic and microglial activation and clear vascular protection, while heterozygous carriers showed reduced cerebral amyloid angiopathy, attenuated parenchymal vascular abnormalities, and less microvessel fragmentation compared to typical PSEN1E280A cases. 3 , 11 , 12”
From Plasma extracellular vesicles from APOE3 Christchurch carriers display a protective phenotype in early stages of autosomal dominant Alzheimer's disease (2026) · cites this paper as [12]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The Christchurch case showed a unique pathological phenotype among cases with PSEN1-E280A, with remarkably low pTau pathology in most brain regions except in the visual primary cortex25.”
From Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man (2023) · cites this paper as [25]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This patient displayed extremely high Aβ pathology but minimal Tau burden, hippocampal atrophy and neuroinflammation36,43,44.”
From The APOE-R136S mutation protects against APOE4-driven tau pathology, neurodegeneration, and neuroinflammation (2023) · cites this paper as [43]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Despite high amyloid burden, the carrier exhibited low tau pathology in AD-vulnerable regions, frontal and occipital cortices13, suggesting protective ability of the R136S mutation against tau-induced neurodegeneration.”
From The R136S mutation in the APOE3 gene confers resilience against tau pathology via inhibition of the cGAS-STING-IFN pathway (2025) · cites this paper as [13]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“E3 is the most common APOE variant and does not alter AD risk, while E4 elevates AD risk and E2 reduces AD risk12,13.”
From The R136S mutation in the APOE3 gene confers resilience against tau pathology via inhibition of the cGAS-STING-IFN pathway (2025) · cites this paper as [13]
Experimental — accuracy not yet measured
20 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia > Results > Neuroimaging findings
“Aβ plaque burden appeared to decrease during the three-year follow-up period (Fig. 1D)”
§ Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia > Results > Neuroimaging findings
“D Spaghetti plots of Aβ PET (Pittsburgh Compound B, PiB) measurements at baseline and 2-year follow-up”
Citations
Cites
clusterProfiler: an R Package for Comparing Biological Themes Among Gene Clusters
Yu, G., Wang, L.-G., Han, Y., & He, Q.-Y. (2012) · OMICS: A Journal of Integrative Biology · doi:10.1089/omi.2011.0118 · Cited by 36,259
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123 · cited 1×
“Although the case was classified as Braak VI [4], the distribution was atypical, with the highest density of tau signal in the hippocampus, amygdala and occipital cortex (Brodmann areas 17 and 18) and an unusually low density of pathological tau in other typicallyinvolved structures, including negligible tau signal in…”
BackgroundMcGinnis, C. S., Murrow, L. M., & Gartner, Z. J. (2019) · Cell Systems · doi:10.1016/j.cels.2019.03.003 · Cited by 4,521
Phases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490
Hyman, B. T., Phelps, C. H., Beach, T. G., Bigio, E. H., Cairns, N. J., Carrillo, M. C., Dickson, D. W., Duyckaerts, C., Frosch, M. P., Masliah, E., et al. (2012) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.10.007 · Cited by 3,092
Self-citationKrasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., Beckers, L., O’Loughlin, E., Xu, Y., Fanek, Z., et al. (2017) · Immunity · doi:10.1016/j.immuni.2017.08.008 · Cited by 2,979
Self-citationSingle-cell transcriptomic analysis of Alzheimer’s disease
Mathys, H., Davila-Velderrain, J., Peng, Z., Gao, F., Mohammadi, S., Young, J. Z., Menon, M., He, L., Abdurrob, F., Jiang, X., et al. (2019) · Nature · doi:10.1038/s41586-019-1195-2 · Cited by 2,568 · cited 1×
“Only positive marker genes were considered, and these markers were used with known celltype markers from the literature [12, 19, 20, 23] to carefully assign cluster identities.”
Moreno-Jiménez, E. P., Flor-García, M., Terreros-Roncal, J., Rábano, A., Cafini, F., Pallas-Bazarra, N., Ávila, J., & Llorens-Martín, M. (2019) · Nature Medicine · doi:10.1038/s41591-019-0375-9 · Cited by 1,577 · cited 1×
“The expression of neurogenesis-related genes in these neurons can be contrasted to previous findings in control cases [20, 21] and decreased adult neurogenesis in AD patients [25].”
ResultMassively parallel single-nucleus RNA-seq with DroNc-seq
Habib, N., Avraham-Davidi, I., Basu, A., Burks, T., Shekhar, K., Hofree, M., Choudhury, S. R., Aguet, F., Gelfand, E., Ardlie, K., et al. (2017) · Nature Methods · doi:10.1038/nmeth.4407 · Cited by 1,069
Tau positron emission tomographic imaging in aging and early Alzheimer disease
Johnson, K. A., Schultz, A., Betensky, R. A., Becker, J. A., Sepulcre, J., Rentz, D., Mormino, E., Chhatwal, J., Amariglio, R., Papp, K., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24546 · Cited by 986 · cited 1×
“PiB and FTP PET were prepared and acquired according to previously published protocols [17].”
MethodSelf-citation
Cited by
ApoE in Alzheimer’s disease: pathophysiology and therapeutic strategies
Raulin, A.-C., Doss, S. V., Trottier, Z. A., Ikezu, T. C., Bu, G., & Liu, C.-C. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00574-4 · Cited by 756
Alzheimer’s Disease: An Updated Overview of Its Genetics
Andrade-Guerrero, J., Santiago-Balmaseda, A., Jeronimo-Aguilar, P., Vargas-Rodríguez, I., Cadena-Suárez, A. R., Sánchez-Garibay, C., Pozo-Molina, G., Méndez-Catalá, C. F., Cardenas-Aguayo, M.-D.-C., Diaz-Cintra, S., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043754 · Cited by 336
Emerging roles of innate and adaptive immunity in Alzheimer’s disease
Chen, X., & Holtzman, D. M. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.016 · Cited by 297
Resilience to autosomal dominant Alzheimer’s disease in a Reelin-COLBOS heterozygous man
Lopera, F., Marino, C., Chandrahas, A. S., O’Hare, M., Villalba-Moreno, N. D., Aguillon, D., Baena, A., Sanchez, J. S., Vila-Castelar, C., Ramirez Gomez, L., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02318-3 · Cited by 192
Self-citationCell type‐specific roles of APOE4 in Alzheimer disease
Blumenfeld, J., Yip, O., Kim, M. J., & Huang, Y. (2024) · Nature Reviews Neuroscience · doi:10.1038/s41583-023-00776-9 · Cited by 202
“Furthermore, introduction of the APOE(R136S) mutation, which protects against ADAD 122,123 , markedly reduced the number of DAM, tau pathology and neurode-generation in PS19-APOE4 mice 28 .”
Metadata
- Authors
- Sepulveda-Falla, D., Sanchez, J. S., Almeida, M. C., Boassa, D., Acosta-Uribe, J., Vila-Castelar, C., Ramirez-Gomez, L., Baena, A., Aguillon, D., Villalba-Moreno, N. D., Littau, J. L., Villegas, A., Beach, T. G., White, C. L., Ellisman, M., Krasemann, S., Glatzel, M., Johnson, K. A., Sperling, R. A., Reiman, E. M., Arboleda-Velasquez, J. F., Kosik, K. S., Lopera, F., & Quiroz, Y. T.
- Affiliations
- Harvard University (US)
- University of California, Santa Barbara (US)
- University of California San Diego (US)
- Universidad de Antioquia (CO)
- University Medical Center Hamburg-Eppendorf (DE)
- Banner Sun Health Research Institute (US)
- The University of Texas Southwestern Medical Center (US)
- Banner Alzheimer’s Institute (US)
- Corresponding author
- Quiroz, Yakeel T.
- ORCID
- Sepulveda-Falla, Diego
- Sanchez, Justin S.
- Almeida, Maria Camila
- Boassa, Daniela
- Ramirez-Gomez, Liliana
- Baena, Ana
- Aguillon, David
- Littau, Jessica Lisa
- Beach, Thomas G.
- White, Charles L.
- Ellisman, Mark
- Krasemann, Susanne
- Glatzel, Markus
- Johnson, Keith A.
- Sperling, Reisa A.
- Reiman, Eric M.
- Kosik, Kenneth S.
- Lopera, Francisco
- Quiroz, Yakeel T.
- Venue
- Acta Neuropathologica
- Published
- 2022-07-15
- Volume
- 144
- Issue
- 3
- Pages
- 589-601
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC9381462
- OpenAlex
- W4285589271
- Cited by
- 92
- References
- 39
- Citations by year
- 2026: 10 · 2025: 24 · 2024: 31 · 2023: 22 · 2022: 4
- FWCI
- 12.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Institutional Repository University of Antioquia (University of Antioquia) (submittedVersion, cc-by)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Greater South Information System
- Funders
- National Institute of Aging (R01 AG054671)
- Massachusetts General Hospital Executive Committee on Research
- Alzheimer’s Association Research Grant
- Deutsche Forschungsgemeinschaft (CellNetFAD # 458854216)
- National Institute of Neurological Disorders and Stroke (RF1 NS110048, UH3 NS100121)
- Alzheimer’s Association Research Fellowship
- Universidad de Antioquia
- Fundação de Amparo à Pesquisa do Estado de São Paulo (2019/22819-8)
- Werner Otto Stiftung
- Bundesministerium für Bildung und Forschung (UndoAD)
- Universitätsklinikum Hamburg-Eppendorf (UKE)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- autosomal dominant Alzheimer's disease, tau pathology, cerebral amyloid angiopathy, occipital cortex, RORB, microglial inflammation, age of onset, disease progression, positron emission tomography
- MeSH terms
- Alzheimer Disease, Brain, Homozygote, Humans, Amyloid beta-Peptides, tau Proteins, Positron-Emission Tomography, Apolipoprotein E3
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-01, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-01 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia. https://app.cochat.ai/papers/10.1007/s00401-022-02467-8
- The paper
- Sepulveda-Falla, D., Sanchez, J. S., Almeida, M. C., Boassa, D., Acosta-Uribe, J., Vila-Castelar, C., Ramirez-Gomez, L., Baena, A., Aguillon, D., Villalba-Moreno, N. D., Littau, J. L., Villegas, A., Beach, T. G., White, C. L., Ellisman, M., Krasemann, S., Glatzel, M., Johnson, K. A., Sperling, R. A., . . . Quiroz, Y. T. (2022). Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer’s dementia. Acta Neuropathologica. https://doi.org/10.1007/s00401-022-02467-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.